Current Evidence of Antifungal Prophylaxis and Therapy in Pediatric Patients

Mareva Giacchino; Giuseppe Maria Milano; Francesca Carraro; Stefania Bezzio; Anna Pegoraro; Franco Aversa; Simone Cesaro

doi:10.4081/pr.2011.e6

Pediatric Reports is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Article

10 March 2011

Current Evidence of Antifungal Prophylaxis and Therapy in Pediatric Patients

and

Pediatric Hematology Oncology and Bone Marrow Unit, Ospedale Infantile Regina Margherita, Torino, Italy

Pediatric Oncohematology and Bone Marrow Unit, Azienda Ospedaliera di Perugia, Italy

Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

Author to whom correspondence should be addressed.

Pediatr. Rep.2011, 3(1), e6;https://doi.org/10.4081/pr.2011.e6

Version Notes

Order Reprints

Abstract

Invasive fungal infections (IFI) are an important complication in pediatric haematological and oncological patients who undergo intensive chemotherapy for leukemia, solid tumour at advanced stage or relapsed, and hematopoietic stem cell transplantation. The incidence of IFI is lower than bacterial infection but mortality rate remains high. This review is designed to help paediatric oncologists in choosing the appropriate anti-fungal strategy and agents for prophylaxis, empirical, pre-emptive and specific therapy on the basis of published evidence.

Keywords:

fungal infection; pediatric malignancy

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Guidelines for the Management of Bacterial and Fungal Infections during Chemotherapy for Pediatric Acute Leukemia or Solid Tumors: What Is Available in 2010?

Association of Environment and Place of Birth with Asthma in Chinese Immigrant Children